Scaling AI in Life Sciences: Why Data Infrastructure Determines Success

According to Deloitte’s 2026 Life Sciences Outlook, only around 22% of life sciences leaders have successfully scaled AI across their organizations and a mere 9% have achieved significant financial returns from it [1]. The gap between a promising pilot and a production-grade system is rarely about algorithms. It is almost always about infrastructure.

The Real Bottleneck: Data Spaghetti

In most pharmaceutical and CRO environments, life sciences data infrastructure is fragmented across legacy laboratory information management systems (LIMS), clinical platforms, and external repositories. Each source may use different formats, naming conventions, metadata standards, and quality controls. Some datasets are well documented. Others are understood only by the team that originally generated them.

For AI in life sciences, this is a serious problem. Models learn from the structure and assumptions embedded in data. If the data is incomplete, poorly labeled, or affected by uncontrolled batch effects, the model may learn technical artifacts instead of meaningful biological patterns.

In single-cell omics, for example, preprocessing choices and batch correction methods can materially shift downstream gene-importance profiles, causing models to rationalize technical noise as biological insight [2]. In imaging workflows, differences in instruments, staining protocols, or acquisition settings may corrupt the signal a model learns. The breakthrough of AlphaFold was only possible because it was built on decades of curated structural data from the Protein Data Bank (PDB) — one of the most complete and consistently annotated scientific databases in existence [9]. Without that kind of foundation, even sophisticated models generate misleading results.

AI-Ready Data: Computable, Not Just Stored

Many organizations begin by trying to standardize their data. Standardization helps, but it is only part of the work. For AI to scale, data needs to become computable.

As defined by the European Molecular Biology Laboratory (EMBL), computable data is “data which has appropriate meta-data and knowledge enrichment; and that is standards-based, structured and complete, deployed in a scalable manner” [2]. This definition captures what AI-ready data actually requires in practice: interpretability by machines with minimal manual intervention.

This context matters because life sciences data is rarely self-explanatory. A gene expression matrix, microscopy image, or assay result may be technically readable but scientifically ambiguous without the right metadata and experimental context.

AI-ready data is therefore a managed product, one that needs ownership, documentation, quality control, and lifecycle management. Building this kind of AI drug discovery infrastructure and clinical data foundation is what separates organizations that can scale from those that keep running pilots [3].

From Pilots to Production: The MLOps Gap

A successful AI pilot can be built with a small team, a defined dataset, and a controlled objective. A production-grade AI system needs to operate under changing real-world conditions. This is where most life sciences organizations encounter the MLOps deficit.

Transitioning a model from a local notebook to a high-throughput clinical or research workflow exposes a range of engineering bottlenecks. Post-hoc explainability methods can introduce significant computational overhead, sometimes rendering them impractical for time-sensitive clinical workflows [5]. Infrastructure that was not designed for scale will fail at scale.

Data and model lineage

Teams need to trace which data was used, how it was processed, which model version generated an output, and what assumptions were built into the workflow. This is essential for reproducibility and regulatory review.

Model drift monitoring

Performance degrades when new data differs from the data used during development. Drift monitoring helps teams detect when a model may no longer be reliable [6].

Validation workflows

A tool used for exploratory research does not need the same validation approach as a tool supporting clinical decision-making. Still, every use case needs clear acceptance criteria and a shared understanding of risk — aligned with GAMP 5 principles for regulated environments.

Scalable deployment

A notebook proves that a method works. It cannot support a high-throughput workflow on its own. Production-grade AI systems need stable APIs, compute infrastructure, access controls, monitoring, and integration with tools already used by scientists, clinicians, or operational teams.

Without this engineering layer, AI remains fragile, impressive in a demo, but difficult to repeat, maintain, or trust.

Engineering for Trust: Beyond the Black Box

There is a persistent tension between the accuracy of deep learning models and the requirement for Explainable AI (XAI) demanded by clinicians and regulators [5]. More importantly, even explainable models can fail in ways that are hard to detect.

Models can learn shortcuts: relying on site-specific tokens like scanner differences in radiology rather than actual pathology. In genomics, modest shifts in data distribution can trigger attribution flipping, completely altering which features the model considers important [5]. In those cases, the deeper issue is that the system may be answering the wrong question.

The regulatory environment is reinforcing this direction. The FDA’s January 2025 draft guidance on AI-enabled medical devices and the EU AI Act -applicable from August 2026 — create an immediate mandate for auditability and risk control in AI drug discovery infrastructure and clinical AI systems alike. The UK MHRA’s AI Airlock sandbox offers one model for testing complex AI systems in a controlled, collaborative regulatory environment before full-scale deployment.

Shift-Left Governance: Build Compliance In, Not On

Shift-left governance means embedding regulatory, ethical, quality, and risk considerations early in the development lifecycle, before the system becomes difficult to change. Strong data governance is what makes AI deployable in practice.

The benefit is practical. Teams avoid building AI solutions that look technically promising but cannot be deployed because life sciences data infrastructure, validation, or governance requirements were not addressed in time [7].

Federated Learning and the Data Silo Problem

Data fragmentation is not always a problem that can be solved by centralizing everything. In many life sciences and healthcare contexts, patient privacy, data ownership, contractual restrictions, and security requirements limit how data can be combined across institutions or geographies.

Federated learning offers a reusable architectural pattern for this challenge: models learn from data distributed across different locations without requiring all data to be moved into one central repository. The MELLODDY project, which aggregated 2.6 billion data points across 10 pharmaceutical companies without sharing proprietary compound data, demonstrates that production-grade AI models can be trained on decentralized datasets at scale [10].

These approaches are not a universal solution. They introduce their own engineering complexity, governance requirements, and performance considerations. The broader principle, however, applies across all architectures: scalable AI infrastructure must reflect how data can actually be accessed, governed, and used.

Human-Centered Design: The Adoption Problem

Even technically strong AI systems fail when they do not fit the way people work. Scientists, clinicians, and operational teams do not need another disconnected dashboard. They need tools that reduce friction, support decisions, and respect the complexity of their workflows.

A critical element of successful deployment is positioning AI as a tool that augments expertise rather than replaces judgment. Organizations that engage early adopters, co-design interfaces with end users, and surface relevant context, model uncertainty, data quality indicators, confidence levels, alongside predictions build bottom-up momentum and reduce resistance [7].

A Practical Framework for Scaling AI in Life Sciences

Fig 1. Five layers needed to scale AI in life sciences

1. Data foundation

Create reusable, well-described, quality-controlled data assets. Prioritize metadata, lineage, interoperability, and clear ownership. Treat important datasets as products that can support multiple use cases. This is the core of any robust life sciences data infrastructure.

2. Scientific and technical alignment

Bring domain experts, data scientists, engineers, and product owners into the same workflow. AI in life sciences needs both biological relevance and engineering reliability. The shortage of professionals with genuine interdisciplinary expertise, combining AI engineering with biology, chemistry, or clinical research, remains one of the most significant constraints on scaling [1].

3. MLOps and platform capabilities

Build reusable components for data pipelines, model training, evaluation, deployment, and monitoring. Avoid rebuilding infrastructure from scratch for every pilot. Top-performing organizations invest the early months defining platform blueprints, an upfront cost that accelerates every subsequent use case [8].

4. Governance and validation

Define intended use, risk level, validation requirements, auditability, and human oversight early. Align with applicable regulatory frameworks. Make data governance in pharma and life sciences part of the development lifecycle, not a final checkpoint.

5. Adoption and workflow integration

Design AI around the people who will use it. Integrate outputs into existing workflows, provide context, and make limitations visible.

Conclusion

Scaling AI in life sciences requires a shift from isolated experimentation to production-grade systems. Better models matter, but they are only one part of the equation. The real differentiator is the infrastructure that makes AI usable: computable data, robust MLOps in life sciences, shift-left governance, regulatory alignment, and human-centered workflows.

For life sciences teams planning their AI roadmap, the key question is not only what model to build next. The more important question is whether the organization has the life sciences data infrastructure, engineering workflows, and data governance needed to make AI reliable at scale.

References

1. Lyons P., Konersmann T., Jacobson S., Kleyn N., Rekhraj K., Gosalia D. 2026 Life Sciences Outlook. Deloitte Insights. 2025. Available from: https://www.deloitte.com/us/en/insights/industry/health-care/life-sciences-and-health-care-industry-outlooks/2026-life-sciences-executive-outlook.html
2. AI in biology and health: opportunities and challenges. High level roundtable discussion. EMBL. 2024. Available from: https://www.embl.org/documents/wp-content/uploads/2024/02/AI-in-biology-and-health-opportunities-and-challenges.pdf
3. Liu T, Li W. Applications and challenges of artificial intelligence in life sciences. SHS Web Conf. 2024;187:04007. Available from: https://www.shs-conferences.org/articles/shsconf/abs/2024/07/shsconf_essc2024_04007/shsconf_essc2024_04007.html
4. Factors hindering AI adoption in life sciences: 2023–2026. IntuitionLabs. 2025. Available from: https://intuitionlabs.ai/articles/ai-adoption-life-sciences-barriers
5. Krejcar O, Abdullah J, Namazi H. Implementing XAI in life sciences: Key challenges and pathways to solutions. Artif Intell Life Sci. 2026;9(100153):100153. https://doi.org/10.1016/j.ailsci.2026.100153
6. Scaling gen AI in the life sciences industry. McKinsey & Company. Available from: https://www.mckinsey.com/industries/life-sciences/our-insights/scaling-gen-ai-in-the-life-sciences-industry
7. Conde H. Challenges and opportunities of implementing AI in the life sciences and pharmaceutical industries. LinkedIn. 2026. Available from: https://www.linkedin.com/pulse/challenges-opportunities-implementing-ai-life-sciences-hugo-conde-zq6ge/
8. Wang T, Zhang X, Wang Y, Peng J. Recent progress and challenges of artificial intelligence in bioinformatics and new medicine. Applied Sciences. 2025;15(17):9598. https://doi.org/10.3390/app15179598
9. Jumper J, Evans R, Pritzel A, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596:583–589. https://doi.org/10.1038/s41586-021-03819-2
10. Simm J, Klambauer G, Arany A, et al. Splitting chemical structure data sets for federated privacy-preserving machine learning. Journal of Cheminformatics. 2021;13:96. https://doi.org/10.1186/s13321-021-00576-2